C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Markets Daily

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCCGet Free Report) have received an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $10.67.

Several equities research analysts have issued reports on the stock. Wells Fargo & Company upgraded shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $8.00 to $12.00 in a research note on Thursday, December 19th. Stephens initiated coverage on C4 Therapeutics in a report on Monday, November 18th. They set an “equal weight” rating and a $4.00 target price on the stock.

Get Our Latest Research Report on CCCC

Institutional Investors Weigh In On C4 Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in C4 Therapeutics during the second quarter worth approximately $45,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of C4 Therapeutics during the 2nd quarter worth approximately $51,000. Point72 DIFC Ltd bought a new stake in C4 Therapeutics in the 3rd quarter valued at $51,000. Cynosure Group LLC acquired a new stake in C4 Therapeutics during the 3rd quarter valued at $57,000. Finally, Aigen Investment Management LP bought a new position in C4 Therapeutics during the third quarter worth $82,000. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics Price Performance

CCCC stock opened at $3.50 on Tuesday. The stock has a market capitalization of $247.06 million, a P/E ratio of -2.06 and a beta of 2.96. C4 Therapeutics has a fifty-two week low of $3.38 and a fifty-two week high of $11.88. The business has a 50-day moving average of $4.31 and a 200-day moving average of $5.36.

C4 Therapeutics (NASDAQ:CCCCGet Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The firm had revenue of $15.36 million during the quarter, compared to the consensus estimate of $5.95 million. Equities analysts expect that C4 Therapeutics will post -1.52 EPS for the current year.

C4 Therapeutics Company Profile

(Get Free Report

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

Read More